Innovent Biologics has received China’s National Medical Products Administration (NMPA) approval for the New Drug Application ...

Innovent Biologics ( ($HK:1801) ) has provided an update. Innovent Biologics announced that China’s National Medical Products Administration has ...

Final results from the phase 3 CASSANDRA trial presented at the 2025 ASCO Meeting show that the neoadjuvant chemotherapy ...

Liquid biopsy using ctDNA refines risk stratification for patients with residual cancer burden post-neoadjuvant therapy, aiding in treatment decisions. ctDNA-negative status in resistant tumors ...

“PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility,” by Astellas Pharma Inc. News release; Dec. 17, 2025.

Resource and Reimbursement Barriers to Comprehensive Cancer Care Delivery: An Analysis of Association of Community Cancer Centers Survey Data A decision tree model was used to estimate the ...

The approval was based on data from the phase 3 KEYNOTE-671 trial. The Food and Drug Administration (FDA) has approved Keytruda ® (pembrolizumab) for the treatment of patients with resectable (tumors ...

The FDA approved pembrolizumab plus platinum-containing chemotherapy as neoadjuvant therapy, followed by single-agent pembrolizumab as adjuvant therapy after surgery for adults with resectable ...

Disclaimer: Trastuzumab deruxtecan has not been approved by the FDA for the neoadjuvant or adjuvant setting for early-stage, ...

In this review, we provide a concise overview of neoadjuvant systemic therapy in early-stage HER2-positive breast cancer, with a focus on various chemotherapy backbones and de-escalation strategies.